Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.
Paya
C V
CV
Department of Immunology, Mayo Transplant Center, Mayo Clinic, Rochester, Minnesota 55905, USA.
Fung
J J
JJ
Nalesnik
M A
MA
Kieff
E
E
Green
M
M
Gores
G
G
Habermann
T M
TM
Wiesner
P H
PH
Swinnen
J L
JL
Woodle
E S
ES
Bromberg
J S
JS
D020031:Epstein-Barr Virus Infections / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D004854:Herpesvirus 4, Human; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D016377:Organ Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications / Q000821:virology*